17:10:15 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-11-21 Kvartalsrapport 2024-Q3
2024-08-22 Kvartalsrapport 2024-Q2
2024-05-24 Ordinarie utdelning 2CUREX 0.00 SEK
2024-05-23 Årsstämma 2024
2024-05-23 Kvartalsrapport 2024-Q1
2024-02-29 Extra Bolagsstämma 2024
2024-02-22 Bokslutskommuniké 2023
2023-11-23 Kvartalsrapport 2023-Q3
2023-11-14 Extra Bolagsstämma 2023
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-29 Kvartalsrapport 2023-Q1
2023-05-26 Ordinarie utdelning 2CUREX 0.00 SEK
2023-05-25 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2023-02-10 Extra Bolagsstämma 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-25 Ordinarie utdelning 2CUREX 0.00 SEK
2022-05-24 Kvartalsrapport 2022-Q1
2022-05-24 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-26 Kvartalsrapport 2021-Q2
2021-05-28 Ordinarie utdelning 2CUREX 0.00 SEK
2021-05-27 Årsstämma 2021
2021-05-27 Kvartalsrapport 2021-Q1
2021-02-25 Bokslutskommuniké 2020
2020-11-26 Kvartalsrapport 2020-Q3
2020-08-27 Kvartalsrapport 2020-Q2
2020-07-02 Extra Bolagsstämma 2020
2020-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2020-05-28 Kvartalsrapport 2020-Q1
2020-05-28 Årsstämma 2020
2020-02-28 Bokslutskommuniké 2019
2019-11-22 Kvartalsrapport 2019-Q3
2019-08-23 Kvartalsrapport 2019-Q2
2019-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2019-05-28 Årsstämma 2019
2019-05-17 Kvartalsrapport 2019-Q1
2019-04-02 Extra Bolagsstämma 2019
2019-03-01 Bokslutskommuniké 2018
2018-11-23 Kvartalsrapport 2018-Q3
2018-08-24 Kvartalsrapport 2018-Q2
2018-05-29 Ordinarie utdelning 2CUREX 0.00 SEK
2018-05-28 Årsstämma 2018
2018-05-18 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017

Beskrivning

LandDanmark
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
2cureX är verksamma inom cancerbehandling. Idag tillhandahåller bolaget olika verktyg som används av läkare vid behandlingar för att mäta effekt och resistens hos cancerläkemedel på patientens egna cancerceller. Målet är att förkorta behandlingsperioden samt hitta rätt individuell behandling. Idag innehas störst verksamhet på den europeiska marknaden. Huvudkontoret ligger i Köpenhamn.
2023-04-06 08:30:00

2cureX announced today that the company has, together with its technology partners, Hahn-Schickard Institute and the Department of Microsystems Engineering (“IMTEK”) at the University of Freiburg, received a grant from the German Federal Ministry of Education and Research to continue the co-development of an automated system for handling of 3D-micro-tumors (tumoroids) using 2cureX’s IndiTreat® test system.

1M EUR to finalize the development

The German Federal Ministry of Education and Research (Bundesministerium für Bildung und Forschung, BMBF) has awarded the ADAPT-2 project (“Automatisierte Plattform für das 3D Mikrotumor-Handling mit integrierter Analyse zur personalisierten Therapie auf Basis von KI”) with a grant of 1M EUR. This grant follows a previous BMBF grant (ADAPT) of 940,000 EUR that was awarded in 2020. ADAPT-2 will add new features to the present prototype, including advanced AI, and will result in the automation of the IndiTreat® test. The engineering part of the project is being conducted by Hahn-Schickard and the Department of Microsystems Engineering (“IMTEK”) whereas the tumoroid handling and AI algorithms will be provided by 2cureX. According to the terms of the collaboration, 2cureX will retain rights to the developed instrument, and receive 170,000 EUR in cash for its contribution to the project.

Strategic relevance of automating IndiTreat®

2cureX has successfully introduced three CE-IVD marked IndiTreat® tests into the European market. The products assist oncologists in selecting the most efficacious treatment for colorectal cancer. Presently the tests are offered as a service and performed in 2cureX central lab in Copenhagen, and therefore can only be offered within Europe due to sample logistics restrictions. An automated system opens the door to the testing being done at each hospital, therefore allowing geographic expansion into the Asian and American markets. Decentralizing testing is also expected to accelerate the adoption of the technology by hospitals.

“Our collaboration with Hahn-Schickard and IMTEK in the ADAPT project has been very successful and we are excited by the opportunity provided by BMBF to continue the automation of IndiTreat®”, says Fernando Andreu, CEO of 2cureX. And continues: “The development of an automated system will keep us on the leading edge of Functional Drug Sensitivity Testing, and accelerate the uptake in hospitals, allowing also our expansion beyond Europe”.